madman
Super Moderator
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
New injectable and oral options offer eligible men more ways to get proactive about their testosterone health Hims Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for...
Starting today, Hims is closing that gap, providing eligible customers access to three new treatment options, including:
- Two injectable options:
- The compounded product is a twice-weekly subcutaneous injection available for eligible patients, and it's proven to increase testosterone levels within days.*
- The commercial product is a generic testosterone cypionate, taken once a week via intramuscular injection, and can raise T levels in under 24 hours.**
- An oral TRT option— Kyzatrex®, is FDA-approved and has been shown to help up to 96% of men reach normal testosterone levels in just 90 days, with no injections required.***
New injectable and oral options offer eligible men more ways to get proactive about their testosterone health
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the launch of new injectable and oral testosterone replacement therapies (TRT) for eligible men. It’s the largest expansion of the company’s men’s health program since first introducing the category last September, giving eligible men more options to treat low testosterone in partnership with licensed providers through Hims.
An estimated 20 million men1,2 in the U.S. are affected by low testosterone, which, when left untreated, can lead to feelings of lower energy, reduced muscle mass, lower sex drive, and erectile dysfunction. For years, stigma kept many men quiet about these symptoms, but new research suggests men are starting to open up. A new survey commissioned by Hims of 2,000 U.S. men ages 18 and older found that men are speaking more openly about testosterone, and the hormonal shifts that come with age. When asked about what they actually want, 79% of men surveyed say more energy is a higher priority than more muscle,3 so they can show up more fully at work, in their hobbies and with the people who matter most. Despite this progress, awareness of treatment hasn’t caught up: the same study shows fewer than half of men surveyed (45%) say they're familiar with specific low T treatments.4
“Good testosterone care starts with a strong relationship between a customer and their provider,” said Mike Chi, Chief Operating Officer at Hims & Hers. “Everything we’ve developed, from at-home testing and follow-up labs to ongoing provider support, is designed to make that relationship easier to start and sustain. With injectable and oral TRT, more men can start, and stay on track, with support at every step.”
These new options build on Hims’ existing Testosterone Rx+ treatment, which includes enclomiphene, an ingredient shown to double testosterone levels^ by boosting the body’s natural hormone production. Since introducing its testosterone offering, Hims has focused on reaching the many men living with low T, building an experience around at-home blood collection and provider-guided treatment that adapts over time. That approach is resonating. As of the second quarter, testosterone was scaling faster than any specialty outside of weight loss, just three quarters after its launch.%
“Different men need different care approaches, from encouraging the body's own testosterone production to replacing testosterone directly," said Pete Stahl, MD, SVP of Men's Health. "Our full set of treatment options gives our partnered clinicians more ways to deliver personalized, proactive care for testosterone deficiency to our customers.”
Many men with low testosterone go undiagnosed, often because getting tested has traditionally meant booking an appointment, going to a lab, and raising a sensitive topic in person. Hims built its diagnostic experience to remove those barriers, with clinical rigor at every step. Every customer begins with a detailed medical intake that assesses symptoms and screens for risk factors. Customers then collect a blood sample at home with a simple-to-use Tasso® device, an FDA-cleared, push-button collector worn on the upper arm, with no lab visit or venous draw required. From that single, small sample, Hims’ labx tests 22 biomarkers, including total and free testosterone, SHBG, an advanced lipid panel, and glycemic markers, giving providers a far fuller picture of a man’s health than a standalone testosterone test. A licensed provider reviews symptoms, health history, and lab results in a live visit, and treatment is only prescribed when it’s medically appropriate. For those who begin treatment, ongoing assessments, follow-up lab testing, and continued access to a support team helps providers track progress and adjust care over time.
